Table I.
Multivariable-adjusted odds ratios (aORs)∗ of diagnosis era (COVID-19 vs pre-COVID-19) by melanoma characteristics
| aOR∗ (95% CI) | P-value† | |
|---|---|---|
| Melanoma subtype | ||
| Superficial spreading | Ref | - |
| Nodular | 1.42 (1.06-1.89) | .009 |
| Acral lentiginous | 1.04 (0.53-2.01) | .95 |
| Other/unknown | 1.16 (0.92-1.45) | .18 |
| Thickness (mm) | ||
| ≤1.0 | Ref | - |
| >1.0-2.0 | 1.13 (0.88-1.44) | .26 |
| >2.0-4.0 | 1.41 (1.07-1.86) | .006 |
| >4.0 | 1.50 (1.10-2.04) | .003 |
| Unknown | 1.04 (0.34-3.24) | 1 |
| Ulceration‡ | ||
| No | Ref | - |
| Yes | 1.40 (1.13-1.73) | <.001 |
| Biopsy margin status | ||
| Negative | Ref | - |
| Positive | 1.13 (0.89-1.44) | .38 |
| Unknown | 0.85 (0.53-1.36) | .61 |
| Mitotic rate (mitoses/mm2) | ||
| 0 | Ref | - |
| 1 | 1.07 (0.82-1.40) | .81 |
| >1 | 1.41 (1.17-1.71) | <.001 |
| AJCC clinical stage§ | ||
| I | Ref | - |
| II | 1.37 (1.10-1.72) | .002 |
| III | 1.01 (0.69-1.48) | 1 |
| IV | 1.44 (0.94-2.23) | .09 |
| Unknown | 1.48 (0.73-3.01) | .28 |
| SLNB result | ||
| Negative | Ref | - |
| Positive | 0.89 (0.62-1.26) | .98 |
| Other/unknown | 0.35 (0.03-4.62) | 1 |
| SLNB not performed | 0.81 (0.68-0.95) | .008 |
Bold values indicate statistically significant results, defined as P < .05.
AJCC, American Joint Committee on Cancer; aOR, adjusted odds ratio; CI, confidence interval; mm, millimeters; ref, reference; SLNB, sentinel lymph node biopsy.
All outcomes adjusted for age at diagnosis, sex, race, ethnicity, and personal and family history of melanoma.
P-values were computed using a Wald test for the regression coefficients (log odds ratios). P-values and 95% confidence intervals were adjusted using the false discovery rate method to account for multiple comparisons.
There was not enough data for “unknown” ulceration status to estimate odds ratios.
The eighth edition American Joint Committee on Cancer (AJCC-8) melanoma staging system was used.